NasdaqGS:SRPTBiotechs
How the Roche Shipment News Impacts Sarepta Therapeutics Valuation in 2025
If you’re sitting on the fence with Sarepta Therapeutics stock, you’re definitely not alone. There’s been no shortage of drama lately, and that’s had a real impact on SRPT’s price swings. In the last month, Sarepta has climbed an impressive 43% thanks to key regulatory developments and fresh optimism on the company’s flagship gene therapy, Elevidys. Yet, looking back further, you’ll notice it’s been a bumpy ride, with the one-year return still down 85% and volatility riding high due to both...